Active Ingredient History

  • Now
Enclomifene (INN), or enclomiphene (USAN), is a nonsteroidal selective estrogen receptor modulator of the triphenylethylene group which was under development for the treatment of male hypogonadism and type 2 diabetes. By December 2016, it was in preregistration and was under review by the Food and Drug Administration in the United States and the European Medicines Agency in the European Union. In January 2018, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended refusal of marketing authorization for enclomifene for the treatment of secondary hypogonadism. In April 2021, development of enclomifene was discontinued for all indications.   Wikipedia

  • SMILES: CCN(CC)CCOc1ccc(cc1)\C(=C(\Cl)/c2ccccc2)\c3ccccc3.OC(=O)CC(O)(CC(=O)O)C(=O)O
  • Mol. Mass: 598.09
  • ALogP: 6.56
  • ChEMBL Molecule:
More Chemistry
enclomiphene citrate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue